The Swiss pharmaceutical group Roche reported 2025 first quarter sales of CHF 15.4 billion ($18.6 billion) for an increase of 7% in Swiss francs and 6% at constant exchange rates. Group sales were driven by higher demand for newer medicines and diagnostics. The strongest performers in its pharmaceutical division were Phesgo, a combination therapy for breast cancer, Vabysmo, a drug for severe eye diseases, and the allergy treatment Xolair. For the year as a whole, group sales are expected to increase in a mid-single digit range at constant exchange rates.
